Journal
JOURNAL OF CLINICAL INVESTIGATION
Volume 120, Issue 9, Pages 3084-3087Publisher
AMER SOC CLINICAL INVESTIGATION INC
DOI: 10.1172/JCI44266
Keywords
-
Categories
Funding
- NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL031950, R01HL077753, R01HL060742] Funding Source: NIH RePORTER
- NHLBI NIH HHS [R01 HL060742, HL-077753, R01 HL077753, HL-31950, HL-060742, P01 HL031950] Funding Source: Medline
Ask authors/readers for more resources
Recombinant activated protein C (aPC) improves the survival of patients with severe sepsis, but the precise molecular and cellular targets through which it mediates this effect remain incompletely understood. In this issue of the JCI, Kerschen et al. show that endothelial cell protein C receptor (EPCR) is specifically expressed by mouse CD8(+) dendritic cells and that these coordinators of host responses to systemic infection are required for aPC to provide protection against the lethality of sepsis. An additional study, by Cao and colleagues, recently published in the JCI, implicates the leukocyte integrin CD11b in the pathways by which aPC mediates antiinflammatory effects in the context of lethal sepsis in mice, suggesting a common thread of synergistic control of innate immune responses by life-saving aPC therapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available